A Single Center, Open Label Study to Evaluate Biodistribution, Pharmacokinetics and Safety of [89Zr]Zr-DFO-AP-101 PET (Positron Emission Tomography) in Healthy Volunteers and Amyotrophic Lateral Sclerosis (ALS) Patients
Latest Information Update: 03 Feb 2025
At a glance
- Drugs AP 101 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions; Pharmacokinetics
Most Recent Events
- 28 Jan 2025 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
- 28 Jan 2025 Status changed from recruiting to active, no longer recruiting.
- 09 Jul 2024 Planned End Date changed from 31 Jul 2024 to 31 Dec 2024.